ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
… USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNAediting technology platform enables the editing of …
… USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNAediting technology platform enables the editing of …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
ProQR will present new preclinical data for Axiomer, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the ASGCT Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
… company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully … filed against a key patent for its ADAR-mediated RNAediting platform Axiomer™. The opposition was filed in …
